CD19 and B-cell non-Hodgkin lymphoma: CD19, a transmembrane glycoprotein regulating B cell activation in an antigen receptor-dependent manner, is an optimal target for CAR-T therapy of B-cell lymphoma, as CD19 is expressed throughout B cell differentiation and frequently during B cell malignant transformation.